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1. ABSTRACT 
 
The intestinal microbiota is a complex ecosystem consisting of numerous species of 
bacteria. Indigenous intestinal microbiota is considered an integral part of the host's 
defence mechanisms. It forms a barrier against pathogen colonization and also influences 
the host’s immunological, biochemical and physiological features. The resident 
indigenous microbiota includes several species of lactic acid bacteria (LAB), which have 
an important protective function in the gut.  
 
Probiotics, defined as “microbial cell preparations or components of microbial cells that 
have a beneficial effect on the health and well-being of the host”, are usually a species of 
LAB. Selected probiotic LAB have been shown to elicit beneficial health effects in 
humans and in murine models. The potential positive effects on dogs’ health have not 
been extensively examined and there are no established guidelines for evaluating these 
effects of canine probiotic LAB.  
 
The present study aimed to develop a method to measure intestinal secretory 
immunoglobulin A (sIgA) in dogs, and to assess the suitability of various in vitro 
methods utilized in human probiotic studies in veterinary probiotic evaluation. Study I 
applied the in vitro intestinal mucus model utilized in human probiotic studies to canine 
use, utilizing jejunal chyme from permanently fistulated dogs. The intestinal mucus 
model was employed also in Study II, when the competitive exclusion of pathogenic 
bacteria was investigated, and again in Study III, which focused on the species specificity 
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of LAB adhesion. This model was found to be suitable in canine in vitro adhesion 
studies.  
 
Competitive exclusion of pathogens is one of the most important beneficial health claims 
of probiotic bacteria. The competitive exclusion study (Study II) suggests that certain 
probiotic LAB reduce the in vitro mucus adhesion of the canine intestinal pathogen, 
Clostridium perfringens. However, increased in vitro mucus adhesion of Campylobacter 
jejuni caused by the tested enterococci may be a cause for concern. 
 
Adhesion of probiotic LAB has earlier been shown to be host specific. Host specificity 
has been considered to be essential for probiotic LAB to exert their beneficial health 
effects. This is why it is recommended as one of the selection criteria for probiotic LAB. 
Results from Study III showed the adhesion properties to be LAB strain dependent rather 
than animal species dependent. 
 
In humans and experimental rodent models, probiotic LAB have been shown to improve 
the intestine’s immunological barrier, particularly immunoglobulin A (IgA) responses. 
Serum IgA (S-IgA) or fecal sIgA are not considered to be reliable when assessing 
intestinal IgA responses. Study IV developed a novel method to measure mucosal IgA in 
duodenal brush samples obtained via endoscopy. A marked variance in sIgA 
concentrations was measured from different sites of duodenal mucosa. Moreover, it can 
be concluded that neither S-IgA nor salivary sIgA are suitable parameters for the 
assessment of duodenal sIgA competence in dogs. 
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2. ABBREVIATIONS 
 
CFU  Colony forming units 
ELISA  Enzyme-linked immunosorbent assay 
EHEC  Enterohemorrhagic Escherichia coli 
HEPES  N-2-hydroxy-ethylpiperazine-N’-2-ethanesulfonic acid 
HH HEPES-Hanks buffer  
Ig  Immunoglobulin 
LGG  Lactobacillus rhamnosus GG 
OD  Optic density 
MRS  De Man, Rogosa, Sharpe broth 
O/N  Over-night  
sIgA  Secretory immunoglobulin A 
S-IgA  Serum immunoglobulin A 
SRID        Single radial immunodiffusion  
SD  Standard deviation 
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 4. INTRODUCTION 
 
The intestinal microbiota is a complex ecosystem consisting of numerous species of 
bacteria. Little is known about the composition of canine intestinal microbiota since most 
of the studies have focused either on humans or rodent models. In humans, it is estimated 
that there are more than 400 known bacterial species present in the gut (Moore and 
Holdeman 1974, Berg 1996, Vaughan et al 2000). The actual number of microbes is 
likely to exceed this figure as the estimation is based on traditional cultivation methods 
available during the mid-1970s. Total numbers of bacteria amount to as many as 1014 
cells, forming approximately 95% of all the cells of an individual human or animal. As a 
result, the intestinal microbiota outnumbers the body’s eucaryotic cells (Savage 1977, 
Blaser and Musser 2001). This system is in a finely tuned equilibrium  within itself and in 
relation to the host (Salminen and Deighton 1992).  
 
In the early 20th century, Elie Metchnikoff, a Russian zoologist, bacteriologist and Nobel 
laureate, postulated that “friendly” intestinal bacteria contributed to the longevity of the 
Georgian people. He believed that consuming fermented milk products rich in lactic acid 
bacteria (LAB) is beneficial for humans as they reduce the number of harmful, “toxin-
producing” bacteria in the gut (Metchnikoff 1907). At present, the indigenous intestinal 
microbiota is considered an integral part of the host defence mechanisms. It forms a 
barrier against pathogen colonization and also influences the host’s immunological, 
biochemical and physiological features (Tannock 1999). Disturbances in the gut 
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microbiota may result in diarrhoea, malabsorption and chronic intestinal inflammation 
(Johnston 1999). Acute diarrhoea may be fatal as pathogens may invade the host’s 
tissues, causing bacteremia and sepsis. 
 
The resident indigenous microbiota includes several species of LAB, which have an 
important protective function in the gut. To be able to induce a disease, a pathogen must 
first colonize the intestinal mucosa. In order to do this, it must first overcome the host 
defence mechanisms (e.g. gastric acidity, bile acids, gut peristalsis, secretory 
immunoglobulin A), and beat the established mucosal microbiota in the competition for 
nutrients and suitable adhesion sites on the gut mucosa. LAB are documented to have a 
marked role in pathogen prevention in the intestinal ecosystem. In humans, the best-
documented health effect of many specific probiotics has been a reduction in the risk of 
acute gastroenteritis or a shortening of the duration of viral or bacterial diarrhoea (For 
reviews see: Salminen and Deighton 1992, Guandalini et al 2000, Alvarez-Olmos and 
Oberhelman 2001, Reid and Burton 2001, Tagg and Dierksen 2003).  
 
Adhesion to the intestinal mucosa is considered one of the main mechanisms by which 
probiotic LAB exert their beneficial health effects. It is regarded important for transient 
colonization (Alander et al 1999), enhanced healing of the damaged gastric mucosa 
(Elliott et al 1998), modulation of the immune system (Schiffrin et al 1997, O’Halloran et 
al 1998, Perdigon et al 2002) and antagonism against pathogens (Jin et al 2000). Many 
studies have examined the adhesion properties of probiotic LAB. As mucosal adhesion is 
very difficult to study in vivo, several in vitro methods have been developed. Samples of 
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intestinal mucosa, epithelial cells and mucus can be used for adhesion assay (Tuomola 
1999c). 
 
Probiotics are being widely utilized in farm animal husbandry to improve breeding 
performance in stressful conditions such as high animal concentration, early weaning or 
rapid growth (Fuller, 1989). Probiotics are also considered beneficial for canine health in 
similar situations, although scientific evidence from controlled trials is very scarce 
(Barrows and Deam 1985, Biourge et al 1998, Pasupathy et al 2001, Benyacoub et al 
2003, Vahjen and Männer 2003). For admission to the European common market, 
probiotics intended for animals have to be tested according to the Feed Additive 
Directive 70/524/EC. However, it has been evident that there are currently no criteria 
available to assess their effectiveness (Lahrssen and Zentek 2002).  
 
As adhesion to intestinal tissue is one of the cornerstones of probiotic function, it is 
therefore regarded as one of the main selection criteria for probiotic LAB. Other criteria 
include an ability to survive gastric acid and bile, activity against pathogens and mucosal 
immunomodulation (Saarela et al 2000, Dunne et al 2001). At present, these criteria are 
applied only to probiotics intended for human consumption. Such guidelines would also 
benefit research and development in the veterinary probiotic field. Demand for 
appropriate strain identification and nomenclature; clinically evaluated and reported 
health effects; documented ability for the strain to survive and temporarily colonize the 
host, and safety for both animals and humans are applicable also to probiotics intended 
for animal consumption.  
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 5. REVIEW OF THE LITERATURE 
 
5.1 Lactic acid bacteria and probiotics 
 
Lactic acid bacteria (LAB) are gram-positive, aerotolerant, catalase negative rods or 
cocci producing lactic acid as their main fermentation product. They form a heterogenous 
group of bacteria, the genera of Enterococcus, Lactobacillus, Lactococcus, Leuconostoc, 
Pediococcus Streptococcus and Weissella being the best known. Most LAB are non-
pathogenic and they are associated with wide variety of sources, such as plant material 
and various foods (Axelsson 1998). They also form a substantial part of the intestinal 
microbiota and are believed to have a major effect on host’s well-being (Vaughan et al 
2002). The knowledge of the canine intestinal LAB is scarce, as only few studies have 
addressed the canine intestinal microbiome, including LAB (Smith 1965, Clapper 1970, 
Davis et al 1977, Benno et al 1992, Greetham et al 2002). In addition, many of these 
studies date back to times when molecular techniques were not available, and LAB were 
not identified to species level. Also the classification and nomenclature of LAB has been 
subjected to various changes during recent years. In a recent study, fecal microbiota of 
four Labrador retrievers was examined and S. bovis and L. murinus were found to be the 
most prevalent culturable LAB species (Greetham et al 2002). 
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Bifidobacteria, although they share much similarity with LAB, are strictly speaking not 
LAB because of the different metabolic path way by which they produce lactic acid; the 
fructose-6-phosphate pathway (Ballongue 1998) 
 
The word “probiotic” originates from the Greek word meaning “for life”. Probiotics are 
defined as “microbial cell preparations or components of microbial cells that have a 
beneficial effect on the health and well-being of the host” (Salminen et al 1999).  
Probiotics are most often of lactic acid bacteria (LAB); bacteria belonging to other genera 
(e.g. Bacillus) and yeasts (e.g. Saccharomyces) have also been used.  
The term "probiotic” was first used in its current meaning in the mid-1970s (Parker 
1974). The term was again revised by Fuller (1989), who defined it as a “live microbial 
feed supplement that beneficially affects the host animal by improving its intestinal 
microbial balance”. Later, this definition was broadened to cover humans (Havenaar and 
Huis in’t Veld 1992) and specifically probiotic functional foods (Salminen et al 1998).  
 
Although probiotics were mostly used on domestic animals before they began to be 
successfully used in human health foods, little is known about their beneficial health 
effects on dogs. Apart from this, there are no generally accepted guidelines available to 
assess the in vivo or in vitro effectiveness of potential probiotic bacteria intended for pet 
animal use. Despite this, probiotics are effectively marketed to veterinarians and dog 
owners and are becoming increasingly popular  also in promoting canine health.  
 14
 5.1.1 Beneficial documented health effects related to probiotics intended for human 
consumption 
 
Selected probiotic LAB have been shown to elicit beneficial health effects in humans 
(Salminen et al 1998, Sanders 2003), Table 1. Some of these health claims are better 
scientifically proven than others: for example probiotic L. rhamnosus GG was able to 
reduce the prevalence of atopic eczema by 50% in a placebo-controlled study. In 
addition, several studies have documented that selected probiotics reduce the duration of 
rotavirus diarrhea in children. However, many other probiotics failed to shorten the 
duration of rotavirus diarrhea, suggesting that this favourable effect is dependent on the 
probiotic strain. Probiotics may prevent travellers’ diarrhea, although this claim is not 
strongly supported by the present data. Ability to prevent urinary tract infections, and to 
reduce cholesterol are also listed amongst beneficial health effects, though scientific 
evidence for these claims is rather weak (Ouwehand and Vesterlund 2003). In conclusion, 
some of the beneficial health effects are better documented and therefore widely accepted 
(e.g. prevention of allergies in infants; shortening the duration of rotavirus diarrhea), 
whereas more studies are needed for some other claims (e.g. lowering of serum 
cholesterol; prevention of urinary tract infections). In addition, positive health effects 
may be strain-dependent, and cannot therefore be extrapolated to other probiotic bacteria. 
Also in murine models probiotics have been documented as having several positive 
health effects (For more complete reviews see Erickson and Hubbard 2000, Macfarlane 
and Cummings 2002, Guarner and Malagelada 2003). 
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The possible effects on dogs’ health have not been extensively examined, even though 
probiotics are frequently marketed for canine use as well.  
 
 
Alleviation and prevention of allergies 
Reduction of cariogenity 
Reduction of carcinogenity and mutagenity 
Cholesterol reduction 
Immunomodulation 
Alleviation of lactose intolerance 
Prevention of vaginosis and urinary tract 
infection by antipathogen activity 
Alleviation of hypertension 
Down-regulation of inflammatory responses in 
inflammatory bowel disease 
  Antimicrobial activity in small bowel bacterial 
overgrowth 
 Prevention of kidney stones by altering the 
gut flora influencing oxalate degradation 
Prevention and alleviation of antibiotic-
associated, rotavirus and travellers’ 
diarrhoea 
 
Table 1. Documented beneficial health effects in controlled human studies. Modified 
from Sanders, 2003. 
 
5.1.2 Beneficial documented health effects  in dogs 
 
There are only a few reports of beneficial health effects in dogs. Enterococcus faecium 
SF68 has been documented as enhancing specific immunological responses in young 
dogs (Benyacoub et al 2003) and E. faecalis FK-23 stimulated non-specific immune 
functions in healthy adult dogs (Kanasugi et al 1997). Pasupathy and co-workers (2001) 
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evaluated the effect of Lactobacillus acidophilus on the digestibility of food and growth 
of puppies. They concluded that Lactobacillus supplementation has a favourable effect 
during the active growth period, although differences between the study group and 
control group were not significant.  
 
5.1.3 Adhesion to intestinal mucosa 
 
The mechanisms used by pathogenic bacteria to attach themselves to the intestinal 
mucosa have been broadly examined in order to understand and prevent enteric bacterial 
infections (Mouricourt 1997, Edwards and Puente 1998). The nonpathogenic indigenous 
microbiota in the gut has received much less attention and the exact mechanisms by 
which LAB bind to intestinal mucosa have yet to be clarified. Adhesion to the intestinal 
mucosa, followed by at least transient colonization is considered necessary for probiotic 
LAB to exert their favourable effects as it prolongs the contact period with the host, thus 
allowing more time for the probiotic to exert its beneficial health effects. Adhesion to 
mucosa is regarded as important for transient colonization (Alander et al 1999) enhanced 
healing of the damaged gastric mucosa (Elliott et al 1998), modulation of the immune 
system (Schiffrin et al 1997, O’Halloran et al 1998, Perdigon et al 2002) and antagonism 
against pathogens (Jin et al 2000, Hirano et al 2003).  
 
Mucosal colonization with non-pathogenic resident microbiota is of particular importance 
for the protection of the host against pathogenic invaders. This is best illustrated in 
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animals without normal intestinal microbiota, which considerably are more susceptible to 
infections (Baba et al 1991). 
In a rodent model, colonization of probiotic Bifidobacterium infantis 1222 was reported 
to prevent the intestinal wall colonization of pathogenic Bacteroides vulgatus, one of the 
intestinal commensal pathogens considered to play a role in the development of human 
inflammatory bowel disease (IBD). B. infantis prevented Bacteroides from invading the 
gut epithelium, which could have led to increased systemic antibody responses and the 
development of IBD (Shiba et al 2003).  
 
Lactobacilli able to colonize the gut mucosa also seem to have a potential to affect the 
intestinal immune functions, and ability to colonize the gut mucosa is regarded as a 
valuable selection criteria for immunomodulation (Herias et al 1999, Schiffrin et al 
1997).  
 
5.1.3.1 Non-specific and specific bacterial adhesion 
 
In general, bacterial adhesion can be divided into two parts: non-specific and specific 
adhesion. 
 
Non-specific binding of bacteria is based on van der Waals and electrostatic forces 
between the cell and the mucosal surface, explained by the so-called DLVO-theory. This 
theory postulates that although bacteria are negatively charged, they are still attracted to 
negatively charged host tissue because the attracting van der Waals forces are stronger 
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than the electrostatic repulsion. However, the DLVO-theory originally described the 
attachment of inert particles to a solid substratum but has also been applied to bacteria 
(Busscher and Weerkamp1987). It appears that the interactions between living bacteria 
and mucosa are much more complicated to be explained by the DLVO-theory alone 
(Tuomola 1999c). An additional explanation is based on the hydrophobic molecules on 
the bacterial surface, which counteract the repulsive electrostatic forces, allowing bacteria 
to draw near the negatively charged mucosal This type of an adhesion is considered to be 
weak and reversible (Ofek and Beachey 1995, Vigeant et al 2002). Non-specific bridging 
between a bacterium and substratum may also be due to hydrophobic interactions or 
hydrogen bonding (An et al 2000).  
 
Specific adhesion has been described as “lock and key” interaction between bacteria and 
the host mucosa and is mediated by bacterial adhesins and corresponding receptors in the 
mucosal epithelium (An et al 2000, Dunne 2002). The matching connection between 
receptor and adhesin allow numerous bonds between the bacterium and host cell. The 
binding thus formed is much stronger when compared to non-specific adhesion, as it is 
not likely for all the adhesive bonds to rupture simultaneously. Adhesion can be inhibited 
by altering the structure of adhesins or receptors with enzymes or other chemical 
compounds; or with antibodies mimicking the receptor or adhesin (Beachey 1981). 
Probiotic LAB may employ both types of mechanisms when competing for survival in 
the intestinal mucosa, for example L. crispatus was reported to inhibit the in vitro 
adhesion of E. faecalis due to the combined effect of both bactericidal activity and 
competition for attachment site (Todoriki et al 2001). 
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.  
Bacterial lectin adhesins can be located on cell surface appendages, as in tips of the 
fimbriae in E. coli (Thomas et al 2002). LAB and bifidobacteria do not commonly 
possess such prominent structures; although fimbriae and flagella have been identified in 
some vaginal LAB strains (McGroarty 1994) and Bifidobacterium longum (Schell et al 
2002 ). 
 
Bacteria belonging to L. acidophilus group are documented to have lectin-like proteins in 
the surface layer protein (Yamada et al 1994). Such elements in the surface layer protein 
may contribute to the bacterial adhesion, as they bind to carbohydrate portions of the 
intestinal mucosal layer (Matsumura et al 1999). In the intestine, the mucus layer 
covering the gut epithelium is rich in glycoproteins and glycolipids, providing abundantly 
carbohydrate moieties for bacterial adhesion (Beachey 1981). The exact mechanisms of 
the lactic acid producing bacteria adhesion in the intestinal mucosa are not very well 
characterized. However, L. fermentum was documented to bind to mucus glycoproteins 
isolated from porcine gastric mucus (Henriksson et al 1996), and several lactic acid 
producing bacteria adhered to human ileostomy glycoproteins (Tuomola et al 1999a). 
These findings suggest that glycoproteins in intestinal mucus can act as suitable 
receptors.   
 
Bacterial adhesion is of special importance in the small intestine, where the intestinal 
peristalsis may detach the bacteria from the mucosal wall.  Stressful conditions in the 
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small intestine caused by luminal flow may alter the function of known adhesive proteins 
and may actually enhance the bacterial binding (Isberg and Barnes 2002). 
 
Adhesive structures may also be involved in the immunostimulation triggered by LAB, 
e.g. L. casei strain CRL 431 capable of immunostimulation was found to have protruding 
cell surface structures identified as lectins (Morata de Ambrosini et al 1998). 
 
5.1.4 Host specificity of probiotic LAB 
 
Adhesion of probiotic LAB has been reported to be species specific (Fuller 1973, Barrow 
et al 1980, Mäyrä-Mäkinen et al 1983). Adhesion and at least temporary colonization to 
host tissue is regarded as important factor for the probiotic to induce its beneficial health 
effects. Therefore, host specificity has been considered to be a desirable property for 
probiotic bacteria. It is thus recommended as one of the selection criteria (Salminen et al 
1998, Saarela et al 2000). Despite this criterion, none of the probiotics evaluated in the 
canine studies were of dog origin. However, the demand for species specificity has been 
discussed, although many of the probiotics with most scientific data are of human origin 
(Salminen et al 1998). On the other hand, LAB of human origin have shown good 
adhesive and immunomodulatory properties in rodents (Wagner et al 1997, Dieleman et 
al 2003), and in fish (Nikoskelainen et al 2003).  
 
Even though the importance of host species specificity has been debated, no studies have 
focused on interspecies differences when it comes to the adherence properties of 
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probiotic LAB adhesion although many probiotics – especially products intended for 
animal use - are marketed for more than one species (Anon 2002). 
 
It has been shown that LAB populations in experimental animals (mice and rats) are not 
dependent on genetics but rather are influenced by environmental factors. Such findings 
underline the effect of intestinal microbiota for studies in probiotic trials and a similar 
competitive role for faecal bacteria has been reported in adherence studies using Caco-2 
cells (de Waard et al 2002, Haller et al 2001). The specificity of adhesion properties 
should thus be further clarified prior to using host specificity as a key for selection 
procedures.  
 
5.1.5 LAB adhesion to intestinal mucosa 
 
5.1.5.1 Structure of intestinal mucosa and mucus production 
 
The intestinal lumen is covered by mucous membrane. Its surface epithelium consists of a 
single layer of columnar cells called enterocytes. Scattered between these cells are 
specialized enterocytes, goblet cells, which synthesize and excrete mucus. Mucus acts as 
a lubricant and a protective layer on top of the enterocytes. The production of mucus is a 
constant process as it is lost in faeces and by bacterial degradation (Schummer and Nickel 
1979, Neutra and Forstner 1987). 
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Mucus consists mainly of water (up to 95%) and mucus glycoproteins (mucins; up to 5%) 
that dictate the viscoelastic characteristics of mucus. Additionally, lipids, 
immunoglobulins and salts are present in the intestinal mucus gel (Neutra and Forstner 
1987). Mucins are macromolecules with a peptide core linked to oligosaccharide chains 
through O-glycosidic bonds. Oligosaccharides consist of N-acetyl or N-glycolyl 
neuramine acids, fucose, galactose, N-acetyl glucosamine and N-acetyl galactosamine. 
The sugar composition of mucins varies depending on the host animal, blood group and 
anatomical location. E.g. Bacteroides thetaiotaomicron can also induce the host to add in 
particular fucose to the mucins (Xu and Gordon 2003).  
 
In addition, intestinal bacteria degrade mucins differently, so the composition of mucus 
cannot be regarded as uniform in all species, and varies also along the intestinal tract 
(Forstner 1978). The composition of canine intestinal mucus has not been examined, but 
homologies are reported between canine tracheal mucin glycoproteins and human 
tracheobronchial and intestinal mucin glycoproteins (Verma and Davidson 1993). The 
intestinal mucus layer is also an important part of the host's defence mechanisms, 
protecting the underlying epithelium from bacterial and environmental antigens, 
mechanical damage and digestive enzymes (Deplancke and Gaskins 2001). 
 
Most probiotic adhesion studies have focused on enterocyte adhesion (Salminen et al 
1998). However, mucus covering the enterocytes is the first contact surface for intestinal 
bacteria in the gastrointestinal tract and an important ecological niche for bacterial 
adhesion and potentially also for competitive exclusion (Neutra and Forstner 1987, 
 23
Mikelsaar et al 1998). Mucins can be divided histochemically into neutral and acidic 
mucins. Acidic mucins are further classified as sialomucins or sulphomucins (Niv et al 
1996). Several mucin genes have been identified in humans (Buisine et al 2001). No 
studies exist on the characterization of canine intestinal mucins or mucin genes. 
 
5.1.5.2 Methods for in vitro adhesion studies 
 
LAB adhesion is difficult to study in vivo, which is why several in vitro methods have 
been developed. In general, when using in vitro assays the bacteria are first incubated 
with the substratum to allow the bacterial cells to bind to it. After the bacteria have 
adhered, the unbound bacterial cells are removed and the adhered bacteria enumerated 
(Tuomola 1999c). 
 
Several methods have been utilized to investigate the in vitro adhesion of probiotic 
bacteria. Samples of intestinal mucosa, epithelial cells and mucus can be used for 
adhesion assay. Intestinal tissue samples can be obtained from animals post mortem or 
during celiotomy. However, as this may have a certain ethical burden , also less invasive 
in vitro models simulating the gut mucosa have been developed for bacterial adhesion 
studies. Different in vitro methods have been used for human probiotic characterization. 
Conway and co-workers (1987) used ileal cells from ileostoma patients in their 
lactobacilli adhesion studies. Tissue culture lines of human intestinal origin are widely 
used for bacterial adhesion assays. Commerical cell lines such as Caco-2 and HT-29 are 
readily available and, as similar techniques are utilized, make the results of independent 
study groups more comparable (Tuomola 1999c). The lack of commercially available 
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canine intestinal cell lines hinders this kind of uniform research of intestinal bacterial 
adhesion in dogs. 
 
In vitro evaluation of LAB adhesion to intestinal mucus extracted from human faeces has 
proved to be a suitable model for both studying probiotic adhesion and offering an 
additional indicator of adhesion properties (Kirjavainen et al 1998). In vitro adhesion 
models utilizing both Caco-2 cell cultures and human ileostomy glycoproteins have been 
compared. The adhesive properties of the investigated LAB were found to vary, although 
some strains showed similar adhesion traits. In general, LAB tended to adhere to Caco-2 
cells more readily than to the intestinal glycoproteins (Tuomola 1999a). The method has 
also been used to investigate LAB adhesion in pigs (Blomberg et al 1993) and fish 
(Nikoskelainen et al 2001a). 
 
5.1.5.3 Effect of jejunal chyme on in vitro probiotic adhesion 
 
The canine gastrointestinal tract is constantly challenged by numerous microbial threats 
that may be harmful to the host. Therefore several defence mechanisms in the gut work to 
prevent hostile invaders from entering through the intestinal wall and infecting the 
animal. Secretory IgA (sIgA) has an important role as a first line of defence against 
bacteria entering the intestine. It binds microbial antigens and in this way acts as an 
“antimicrobial paint” that prevents bacteria from adhering to the mucosal surface, thus 
protecting the organism from pathogen colonization and possible invasion (van Egmond 
2001). In addition to sIgA, there are also other antibacterial substances present in the gut 
 25
lumen and mucosa: bile acids and pancreatic enzymes have a notable role in guarding the 
organism against pathogenic bacteria (Schiffrin and Blum 2002). Also other members of 
the innate immunity (e.g. lysozyme, lactoferrin, defensins, antibacterial peptides and 
secretory phospolipase A) are present in the intestinal lumen (Pitman and Blumberg, 
2000). 
 
Probiotic bacteria have to survive these hostile conditions in the stomach and proximal 
duodenum before they reach their potential colonization sites, the small and large bowel. 
In the upper gastrointestinal tract digestive enzymes, intraluminal antibacterial secretions 
and sIgA will try to interfere with the adhesion and colonization of engulfed bacteria. It is 
vital for a probiotic to be able to survive these defensive mechanisms and still be able to 
maintain its adhesive properties. Resistance to bile is generally regarded as an important 
trait when evaluating the probiotic potential of LAB (Chou and Weimer 1999). This can 
be mimicked in vitro by assessing the ability of probiotic bacteria to grow in the presence 
of bile (Dunne et al 2001). However, as bile is not the sole antibacterial factor in the gut, 
it may be relevant to expect other elements in the intestinal chyme to have a considerable 
effect on bacterial adhesion, too. Little is known about the synergy between different 
antimicrobial factors in the intestinal chyme. It might therefore be more appropriate to 
incubate bacteria with intestinal chyme instead of pure bile in order to simulate digestion 
and study its effects on adhesion when evaluating the in vitro properties of potential 
probiotics. 
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5.1.5.4 Competitive exclusion of intestinal pathogens by LAB 
 
Competitive exclusion of pathogens is thought to be one of the most important beneficial 
mechanisms of probiotic bacteria (Adlerberth 2000, Rolfe 2000, Reid and Burton 2002). 
Competitive exclusion by intestinal bacteria is based on bacteria-to-bacteria interaction 
mediated by competition for available nutrients and mucosal adhesion sites. In order to 
gain a competitive advantage, bacteria can also modify their environment to make it less 
suitable for their competitors. The production of antimicrobial substances, such as lactic 
and acetic acid, is one example of this kind of environmental modification (Schiffrin and 
Blum 2002).  
 
To be able to hinder pathogen colonization (and possible subsequent invasion), probiotics 
are believed to have several pathways. They can reduce the viability of a pathogen by 
producing noxious substances, such as lactic acid in the case of L. casei and L. 
acidophilus against EHEC (Ogawa et al 2001); or non-acidic material, e.g. bacteriocins, 
like L. acidophilus that was reported to suppress the growth of Salmonella Typhimurium, 
EHEC and Shigella flexneri (Coconnier et al 1993).  
 
Another way to prevent pathogen colonization is to interfere with their adhesion on the 
mucosal receptors. For example, L. reuteri and L. crispatus competed with the receptor 
sites on the host cell with Salmonella Typhimurium and enterotoxigenic E. coli (Todoriki 
et al 2001); L. reuteri was also effective in preventing the in vitro binding of 
Helicobacter pylori to host cell receptors (Mukai et al 2002). 
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The effect of probiotic LAB on the competitive exclusion of pathogens has been 
demonstrated using human mucosal material in vitro (Tuomola et al 1999a, Hirano et al 
2003), and in vivo in chickens (Hirn et al 1992) and pigs (Genovese et al 2000). Hirano 
and colleagues (2003) showed, that the well-adhering stain L. rhamnosus was capable to 
inhibit the internalization of Enterohemorrhagic E. coli (EHEC) to a human intestinal cell 
line in vitro. The result suggests that a close interaction with the host cells may have been 
responsible for this suppression of EHEC internalization. In Finland, the competitive 
exclusion method has effectively reduced the incidence of salmonellae in broiler chicks  
by (Hirn et al 1992). 
 
As there is emerging evidence of the development and spreading of antimicrobial 
resistance amongst pathogenic bacteria, every attempt to reduce this risk is welcome. The 
use of probiotic bacteria instead of antibiotics is an intriguing prospect in the treatment of 
acute and chronic intestinal disorders, both in humans and animals. This concept has been 
recommended by the World Health Organization (WHO) as an alternative to antibiotics 
for the prevention and control of production-related animal diseases (WHO 1997).  
If specific probiotics can be proven to possess antipathogenic effects, this could reduce 
the use of antimicrobial substances also in canine medicine, thus contributing to a 
lowered risk of spreading antibiotic resistance amongst pathogenic bacteria. 
 
Antibiotics often interfere with the natural homeostasis in the intestinal tract. This may 
lead to antibiotic-induced diarrhoea and possibly even to severe diarrhoea and colitis 
caused by an overgrowth of resistant opportunistic enteric pathogens (Wiström et al 
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2001). Specific probiotics have been shown to be a promising option when treating 
certain antibiotic-responsive intestinal disorders in humans (Cremonini et al 2002). 
Probiotics are also marketed for administration  to antibiotic-medicated dogs in order to 
lessen GI-tract side effects such as diarrhoea (Anon 2002). However, no published 
reports of controlled trials confirm this concept in dogs.  
 
5.2 Evaluation of the effects of probiotic LAB on intestinal sIgA production 
 
5.2.1 Mucosal IgA 
 
IgA is the predominant immunoglobulin of mucosal surfaces (Goldblum 1990, Ginel et al 
1993, Guilford 1996). Most canine IgA is sIgA, which is produced by mucosal 
lymphocytes (Goldblum 1990, Ginel et al 1993, Heremans 1974, Mestecky et al 1999). 
Dimeric IgA is attached to the secretory component on the basolateral side of enterocytes, 
and the complex (sIgA) is transported and released onto the mucosal surface (Toy and 
Mayer 1996, Mestecky et al 1999). In the gut, sIgA plays an important role in the 
intestines' first-line defence against enteric antigens (e.g. bacteria, toxins, viruses and 
dietary antigens). Compared with other immunoglobulins, sIgA is more resistant to 
proteolytic enzymes and does not elicit an inflammatory response (Mestecky et al 1999, 
Isolauri et al 2001). In humans, IgA is divided into two subclasses, IgA1 and IgA2, the 
latter being produced mainly in the lower intestinal tract and being resistant to bacterial 
proteases (Mestecky et al 1999). Similar subclasses have not been identified in dogs.  
Important features of IgA include anti-inflammatory and immune-regulating activities 
(Goldblum1990, Isolauri et al 2001). 
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 Relative IgA deficiency is the most common primary immunodeficiency in man and a 
similar condition has also been attributed to dogs (Ginel et al 1993). In dogs, IgA 
deficiency has been associated with increased susceptibility to infections such as small 
intestinal bacterial overgrowth (SIBO) and inflammatory bowel disease (IBD) (Felsburg 
et al 1985, Batt et al 1991, Campbell et al 1991, German et al 1998). 
 
5.2.2 Assessing the mucosal IgA status in dogs 
 
Serum immunoglobulin A (S-IgA) concentration measurement is broadly used when 
assessing canine immunocompetence (German et al 1998). As most canine S-IgA is 
dimeric and synthesized in gut-associated lymphoid tissue, it is believed that in dogs S-
IgA reflects IgA production in submucosal plasma cells (Heremans 1974).  It has 
therefore been suggested that low S-IgA also indicates low gastrointestinal IgA 
concentration (Whitbread et al 1984). German shepherd dogs with low S-IgA also had 
decreased IgA concentration in the duodenal juice, implying a correlation between S-IgA 
and mucosal sIgA (Batt et al 1991). However, this concept has been questioned by 
German and colleagues (1998) who concluded that the serum immunoglobulin 
concentrations are poor indicators of mucosal Ig secretion in dogs.  
 
Also indices other than S-IgA measurement have been utilized to evaluate intestinal IgA 
status . The quantity of IgA producing plasma cells has been assessed in intestinal 
biopsies by immunohistochemical methods (Guilford 1996). Nonetheless, as the 
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secretory mechanism may be defective in some dogs, the amount of IgA-containing 
plasma cells does not reliably correlate with the amount of mucosal sIgA in gut (Batt et al 
1991).  
 
As both intestines and buccal mucosa are part of the common mucosal immune system, it 
can be hypothesized that salivary sIgA concentration reflects the intestinal sIgA level 
(Mestecky 1993). Saliva samples are easy to obtain and cause no inconvenience to the 
dog. Also faecal IgA concentration measurement has been suggested as an evaluation 
tool for intestinal immunocompetence. However, this method has been criticized as not 
representing the true status of the gut's humoral immune system (Ferguson et al 1995). 
 
Measuring the intestinal sIgA concentration in dogs suffering from chronic enteropathies 
may provide more information about their immunological status. A method assessing 
intestinal sIgA concentration would be useful when examining patients with suspected 
immunodeficiencies. The method should be reliable and allow serial measurements and 
cause minimal discomfort to the dog.  
 
5.2.3 The effect of probiotic LAB on intestinal sIgA responses 
 
In humans and experimental rodent models, probiotic LAB have shown to improve the 
intestine’s immunological barrier, particularly IgA responses (For reviews see: Yasui et 
al 1999, Gorbach 2000, Isolauri et al 2001). Feeding Enterococcus faecium SF68 
supplemented food to young dogs has been documented as increasing faecal IgA 
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concentration, thus implying an improvement in local protective immune response in the 
gut (Benyacoub et al 2003). However, as immunological tests on faecal samples have 
been reported as not characterizing the true status of the gut's humoral immune system 
(Ferguson et al 1995), another method of evaluating the intestinal sIgA level is needed to 
investigate the potential probiotic-induced effects on local sIgA production in the canine 
gut.  
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6. AIMS OF THE STUDY 
 
The aims of the current study were to 
I Study the adhesive properties of probiotic and indigenous canine LAB in the 
intestinal mucus model in vitro 
a) Apply to canine use an in vitro intestinal mucus adhesion model used 
for characterizing human probiotics, utilizing jejunal chyme from 
permanently fistulated dogs 
 
b) Investigate the effect of jejunal chyme on the adhesion of specific 
probiotics and indigenous canine LAB in vitro 
 
c) Investigate the effects of specific probiotics and indigenous canine LAB 
on pathogen exclusion in vitro 
 
d) Investigate host species specificity of specific probiotics and indigenous 
canine LAB in vitro 
 
II To develop a method for assessing intestinal sIgA in dogs and to evaluate indirect 
methods such as salivary or serum IgA assessment as predictors for intestinal 
sIgA concentration. 
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7. MATERIALS AND METHODS 
 
In vitro mucus adhesion model was utilized to evaluate the adhesive properties of 
selected probiotic and canine-derived lactic acid producing bacteria. Intestinal chyme 
from permanently fistulated beagles was used as a source of mucus. In addition, in vitro 
pathogen exclusion study was performed using the same method. Using the same method, 
the species specificity of selected lactic acid producing bacteria was examined. In the last 
study a method for assessing the intestinal sIgA in duodenal samples was developed. 
 
7.1 Animals 
 
Studies I-III were set up to study the adhesion properties of certain commerically 
available probiotics (both human and veterinary products) and indigenous canine LAB. In 
addition these studies sought to evaluate whether the in vitro mucus adhesion model 
would be suitable for bifidobacteria and LAB adhesion studies on canine jejunal chyme.  
For jejunal chyme sampling, permanent nipple valves for intestinal access were operated 
in six healthy beagles (five males, one female) in the mid-jejunum, using the method 
described earlier (Wilsson-Rahmberg and Jonsson 1997). Operations were approved by 
the ethics committee of the University of Helsinki and performed 10 months prior to the 
first study. No changes in the dogs’ health or gastrointestinal function were noticed as a 
result of the valve (Harmoinen et al 2001). 
For the mucus preparation, a sample of approximately 8 ml of jejunal chyme was 
obtained via the valve 2 h postprandial and frozen immediately at -70°C. 
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Study IV was set up to develop a method to assess duodenal sIgA in dogs. The survey 
included twenty dogs, twelve female and eight male, approved for this study. These dogs 
were of nine different breeds and had no previous history of chronic gastrointestinal 
disease and no clinical signs suggestive of any disorder. The dogs were family pets 
(excluding nine beagles), and the owners submitted their dogs to this study voluntarily. 
The beagles were laboratory animals. All dogs were over 12 months old.  
 
The use of experimental animals in these studies was approved by the ethics committee 
of the University of Helsinki. 
 
7.2 Methods 
 
7.2.1. In vitro mucus adhesion assays 
 
The in vitro mucus adhesion model was used for the bacterial adherence assays. The 
method has been modified and described by Kirjavainen and colleagues for human 
probiotic studies (Kirjavainen et al 1998). The method has been widely utilized in human 
probiotic adhesion studies later (Tuomola 1999c, Ouwehand et al 1999, Juntunen et al 
2001), and also in fish (Nikoskelainen et al 2001). It has not been used for canine studies 
earlier, so one of the aims of the present study was to evaluate whether it would be 
suitable for canine in vitro adhesion studies, too. 
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7.2.1.1 Mucus glycoproteins extracted from jejunal chyme and feces (I-III) 
 
Mucus was prepared from canine jejunal chyme essentially as described earlier 
(Kirjavainen et al 1998, Ouwehand et al 1999b). In brief, jejunal chyme was centrifuged 
at 12 000 x g to remove particulate matter. Mucus was precipitated from the clear 
supernatants by dual ethanol precipitation and freeze-dried. Equal amounts of mucus 
from each dog were pooled and a stock suspension of 5 mg ml-1 in HEPES (N-2-
hydroxy-ethylpiperazine-N’-2-ethanesulfonic acid)-Hanks buffer (HH; 10 mM HEPES; 
pH 7.4) was prepared and stored at -20ºC until use. 
 
In Study III, mucus was also isolated from the feces of emu, ostrich, possum (three 
animals from each species), humans (ten individuals), and from the intestines of a 
rainbow trout as described earlier (Kirjavainen et al 1998; Ouwehand et al 1999; 
Nikoskelainen et al 2001). In short, mucus was isolated from the feces by extraction and 
dual ethanol precipitation technique as described by Miller and Hoskins (1981); and from 
rainbow trout intestines by gently scraping the gut surface, particulate matter was 
removed by centrifugation at 13 000 x g. 
 
7.2.1.2 In vitro adhesion assay (I-III) 
 
The adhesion of the radioactively labelled bacteria to immobilized intestinal mucus was 
determined as reported previously (Kirjavainen et al 1998, Ouwehand et al 1999b). 
Briefly, the mucus stocks were thawed and centrifuged to remove any precipitate formed 
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during storage and diluted in HH to a concentration of 0.5 mg ml-1. The mucus was 
passively immobilized on polystyrene microtitre plate wells (Nunc Maxisorp, Roskilde, 
Denmark) by overnight incubation at 4ºC. Excess mucus was removed by washing twice 
with HH. Radiolabelled bacteria were added to the wells and incubated for 1h at 37ºC. 
Non-bound bacteria were removed by washing twice and bound bacteria were released 
and lysed by incubation with 1% SDS-0.1 M NaOH at 1h 60ºC. Radioactivity was 
determined by liquid scintillation and the adhesion expressed as the percentage of 
radioactivity recovered after adhesion, relative to the radioactivity in the bacterial 
suspension added to the immobilized mucus. 
 
7.2.1.3 Effect of pre-treatment with jejunal chyme on Bifidobacterium and LAB 
adhesion 
 
In order to simulate digestion and study its effects on adhesion, bacteria were re-
suspended in clear supernatant from jejunal chyme, a mixture of equal volumes from six 
dogs. After incubation for 1h at 37ºC, the bacteria were washed in PBS and used in an 
adhesion assay as out-lined above (Kirjavainen et al 1998, Ouwehand et al 1999b).  
 
7.2.1.4 Competitive exclusion assay (II) 
 
Competitive exclusion of the canine pathogens by lactic acid producing bacteria was 
examined as described earlier (Ouwehand et al 2001a). Briefly, the mucus stocks were 
thawed and centrifuged to remove any precipitate formed during storage and diluted in 
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HH to a concentration of 0.5 mg ml-1. The mucus was passively immobilized on 
polystyrene microtitre plate wells (Nunc Maxisorp, Roskilde, Denmark) by overnight 
incubation at 4ºC. Excess mucus was removed by washing twice with HH. LAB and 
bifidobacteria without radiolabel were allowed to adhere to the immobilized mucus. 
Wells with PBS only served as control. Non-bound LAB and bifidobacteria were 
removed by washing twice with HH.  Radio-labelled pathogenic bacteria were then added 
to the wells and incubated for 1h at 37ºC. Non-bound pathogens were removed by 
washing twice and bound bacteria were released and lysed by incubation with 1% SDS-
0.1 M NaOH for1h at 60ºC. Radioactivity of the lysed suspension was measured by 
liquid scintillation. The adhesion ratio (%) was calculated by comparing the 
radioactivities of the bacteria added and bound bacteria. Competitive exclusion was 
calculated as the percentage of pathogens bound after the initial adhesion of the lactic 
acid producing bacteria relative to pathogens bound in the absence of pre-adhered LAB 
or bifidobacteria (control). 
 
7.2.1.5 Coaggregation (II) 
 
Because it was observed that some LAB strains increase the adhesion of the canine 
pathogens, possible coaggregation of the LAB and the canine pathogens was 
investigated. The coaggregation test was performed as described earlier (Handley et al 
1987). Bacterial suspensions were prepared as described above. The absorbance at 600 
nm was adjusted to 0.5. Canine pathogens were mixed with an equal volume of an LAB 
strain and incubated for 4 h at 37ºC. Absorbance at 600 nm was determined for the 
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mixture and for the bacterial suspensions alone. Coaggregation (%) was calculated 
according to the following equation: 
 
OD600 (pathogen alone + LAB alone)/2- OD600 (pathogen + LAB combination) x100% 
 OD660 (pathogen alone + LAB alone)/2 
 
Where ‘pathogen alone’ and ‘LAB alone’ represent the optic density at 600 nm (OD600) 
of the separate bacterial suspensions after 4h, and ‘pathogen + LAB combination’ 
represents the OD600 of the mixed bacterial suspension after 4h. 
 
The rational for the method is that when bacteria coaggregate, they become large 
aggregates that are relatively dense and hence sediment, therefore ‘clearing’ the liquid 
phase giving a lower absorbance. The equation calculates the difference in sedimentation 
(as absorbance reduction) between the bacteria on their own and in combination. 
 
7.2.2 Bacteria 
 
7.2.2.1 Bacteria and their growth conditions used in adhesion assays 
 
The lactic acid producing bacteria strains used and their culture conditions are listed in 
Table 2. The bacteria were grown from stocks stored at –75ºC in 40% glycerol (1% 
inocculum). To metabolically radiolabel the bacteria, 10 µl of tritiated thymidine 
([methyl-1,2-3H] thymidine, 120 Ci mmol-1) was added to the medium (1 ml) . After 
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growth, the bacteria were harvested by centrifugation (2000 x g) and washed twice with 
phosphate buffered saline (PBS; pH 7.2; 10 mM phosphate) and resuspended in PBS. The 
absorbance was adjusted to 0.25 ± 0.02 in order to standardize the number of bacteria 
(107-108 CFU ml-1) before use in an adhesion assay. 
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Strain Origin/product Growth 
medium  
Atmosphere Incubation 
time 
Lactobacillus rhamnosus 
GG 
Gefilus  
(Valio Ltd.) 
MRS Anaerobic O/N 
Bifidobacterium lactis Bb12 (Chr. Hansen A/S) MRS Anaerobic O/N 
Lactobacillus reuteri UK1A dog faeces MRS Anaerobic O/N 
Lactobacillus reuteri SK2A dog jejunal chyme MRS Anaerobic O/N 
Enterococcus faecium M74 Lactiferm 
(Medipharm AB) 
MRS Anaerobic O/N 
Enterococcus faecium 
SF273 
Biobak       
(Biofarm OY) 
MRS Anaerobic O/N 
Lactobacillus johnsonii 
La1 
Lactobacillus casei Shirota 
 
Lactobacillus delbrueckii 
subsp. bulgaricus 
LC1 (Nestlé) 
 
Yakult  Singapore 
Pty., Ltd. 
ATCC 11842 
MRS 
 
MRS 
 
MRS 
Anaerobic 
 
Anaerobic 
 
Anaerobic 
O/N 
 
O/N 
 
O/N 
 
Table 2. Lactic acid producing bacteria strains used and their culture conditions 
Abbreviations: MRS: de Man, Rogosa, Sharpe broth; O/N: over-night (12-14h) 
 
 41
7.2.2.2 The growth conditions of bacteria used in competitive exclusion assay 
 
Pathogens used in the competitive exclusion assay were C. perfringens, Salmonella 
enterica Typhimurium, C. jejuni 517C/R and Staphylococcus intermedius EELA 
29972/99; of canine origin. Their culture conditions are listed in Table 1, Study II. 
 
To metabolically radiolabel the bacteria, 10 µl/ml tritiated thymidine ([methyl-1.2-3H-
thymidine, 120 Ci mmol-1) was added to the medium for competitive exclusion assay of 
the canine pathogens . Lactic acid producing bacteria were grown in the absence of 
tritiated thymidine. After growth, the bacteria were harvested by centrifugation (2000 x 
g), washed twice with PBS and re-suspended in PBS. The absorbance at 600 nm was 
adjusted to 0.5 ± 0.02 in order to standardize the number of bacteria (107-108 CFU ml-1) 
before use in the competitive exclusion assay.  
 
7.2.2.3 Bacteria used in coaggregation assay 
 
For the coaggregation assay, the canine pathogens were grown under the same conditions 
as for the competitive adhesion assay, but without added tritiated thymidine.  
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7.2.3 IgA assays 
 
7.2.3.1 Samples 
 
For the duodenal brush samples, a prelubricated microcentrifuge tube (Costar cat. no. 
3207, Corning Inc. NY 14831, USA) was filled with 0.3 ml of Dulbecco’s PBS (Sigma, 
St. Louis, MO, USA). The brush was washed in the PBS solution and the washing was 
stored at -70°C until assay.  
 
Cotton swabs used to collect saliva were allowed to stand in the microcentrifuge tube 
filled with 0.3 ml Dulbecco’s PBS for five minutes and were then squeezed against the 
tube wall to dry the swab. The dilution was stored at -70°C until assay. 
 
7.2.3.2 IgA determinations 
 
IgA concentrations in duodenal samples, saliva and sera were measured by an enzyme-
linked immuno sorbent assay (ELISA). Microtiter plates (Maxisorp, Nunc Intermed, 
Denmark) were coated with polyclonal goat antibody to dog IgA (Nordic Immunological 
Laboratories, Drawer, CA, USA), 0,25 µg/well in 0.05 mol l-1 Na2CO3 buffer (pH 9.2) 
and stored overnight at 4°C. After washing the wells, 100 µl of serial canine IgA standard 
dilutions from 5 to 0.05 mg l-1 (IgA reference standard from the single radial 
immunodiffusion [SRID] kit by Veterinary Medical Research and Development Inc., 
Pullman, WA, USA) and samples (final dilutions 100-fold for duodenal samples and 
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saliva, and 1200-fold for sera) were added to the wells and incubated at room temperature 
for one hour. For all dilutions and washings PBS (0.05 mol l-1 phosphate, pH 7.3), 
containing 0.05% Tween 20 was used. The unbound material was removed with the 
washing buffer, and 100 µl of 400-fold diluted rabbit antibodies to canine IgA (Nordic 
Immunochemical Laboratories) was added and incubated at room temperature for one 
hour. After washings, 100 µl of 1000-fold diluted alkaline phosphatase conjugated goat 
antibody to rabbit IgG (Behring Mannheim, Indianapolis, IN, USA) was added and 
incubated at 37°C for 30 minutes. After washings, the amount of alkaline phosphatase 
fixed to the wells was determined in diethanolamine (1.0 mmol l-1)-magnesium chloride 
(0.5 mmol l-1) buffer, pH 10.0 (Orion Diagnostica, Espoo, Finland), using p-
nitrophenylphosphate (Sigma, St. Louis, MO, USA) as substrate for one hour at room 
temperature. The absorbance of the p-nitrophenolate liberated was measured at 405 nm 
with a 340 ATC microtitration plate reader (SLT, Labinstruments, Vienna, Austria). The 
intra- and interassay coefficients of variation of the assay were 6.1% and 7.9%, 
respectively, and the detection limit of the assay 0.1 mg/ml. 
 
Protein concentrations of duodenal samples were determined using the Folin-Ciocalteau 
phenol reagent (Henry and Szustkiewics 1974). Human albumin (A-1653, Sigma, St. 
Louis, MO, USA) was used as standard. 
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7.3. Statistical analysis 
 
The results from the adhesion experiments are expressed as the average of at least three 
independent experiments. Each experiment was performed with four parallels, to adjust 
for intra-experimental errors. A non-parametric Wilcoxon signed rank test was used to 
evaluate the statistical difference (P<0.05) of competitive exclusion and coaggregation of 
each strain in comparison to the control. All statistical analysis was performed with 
StatView® (Abacus, Berkeley, USA). 
 
The IgA concentrations of the duodenal samples were obtained as a mean of four 
different brush samples, each analysed in triplicate. Associations between different 
parameters were evaluated using the non-parametric Spearman rank correlation test. P-
values of less than 0.05 were considered statistically significant. 
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 8. RESULTS 
 
8.1 Adherence to intestinal mucus 
 
8.1.1 Ability of probiotic bacteria and canine indigenous LAB to adhere to canine 
intestinal mucus in vitro 
 
The adhesion between tested strains was found to range from 0.5% (L. casei strain 
Shirota) to 35% (L. rhamnosus GG). L. rhamnosus GG was found to adhere significantly 
better than all other tested strains (P<0.001). B. lactis Bb12 adhered 9.4%, which is 
significantly different from all other tested strains (P<0.005), while L. casei strain Shirota 
adhered significantly less than all other tested strains (P<0.05). The adhesion percentages 
of all examined LAB are shown in Figure 1, Study I. 
 
8.1.2 Effect of jejunal chyme treatment on lactic acid producing bacteria adhesion 
 
Pre-treatment of the tested lactic acid producing bacteria with clear jejunal chyme 
significantly reduced the adhesion of all tested strains (P<0.05), with the exception of L. 
johnsonii La1 and L. casei strain Shirota. L. rhamnosus GG exhibited still the highest 
adhesion, but this was reduced to 7.8% and was not different from B. lactis Bb12, 4.8% 
adhesion. The adhesion of L. casei strain Shirota was, after pre-treatment with jejunal 
chyme, not different from the Enterococcus strains tested and the lactobacilli isolated 
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from dogs (P>0.05). The results of the jejunal chyme treatment are also expressed in 
Figure 1, Study I. 
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Figure 1. Effects of jejunal chyme treatment on in vitro adhesion of lactic acid producing 
bacteria 
 
8.2 Ability of lactic acid producing bacteria to interfere with pathogen mucus 
adhesion in vitro 
 
All the pathogens tested showed poor to moderate (1.2% to 5.1%) adhesion to the canine 
immobilized intestinal mucus. The average adhesions were as follows: S. intermedius 
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4.5% (2.74% to 5.6%); S. enterica Typhimurium 1.2% (1.1% to 1.4%); C. jejuni 5.1% 
(3.8% to 6.0%) and C. perfringens 3.0% (1.9% to 5.5%). 
Adhesion of C. perfringens was reduced significantly by all tested LAB strains, between 
53.7% and 79.1% of the control without lactic acid producing bacteria (Table 2, Study 
II). When compared with other lactic acid producing bacteria, the reduction was 
significantly lower with the strain L. reuteri UK1A, but not with L. reuteri SK2A. Both 
tested enterococci significantly enhanced the adhesion of C. jejuni, to 134.6% and 
205.5% of the control without LAB, p<0.05 (Table 2, Study II). The adhesion of the 
other tested pathogens was not significantly affected by the lactic acid producing 
bacteria. 
 
8.3 Bacterial coaggregation  
 
Significant coaggregation (p<0.05) was observed for L. rhamnosus GG, B. lactis Bb12 
and L. reuteri UK1A with C. jejuni, (Table 3, Study II). L. reuteri UK1A also exhibited 
coaggregation with S. intermedius (Table 3, Study II). No other significant coaggregation 
was observed. Coaggregation was not related to the enhanced C. jejuni adhesion caused 
by E. faecium strains (Table 3, Study II). 
 
8.4 Host specificity of in vitro mucus adhesion  
 
Adhesion to intestinal mucus of the tested strains was found to range from 1.06% (the 
average adhesion of L. casei Shirota to possum mucus) to 42.1% (the average adhesion of 
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L. rhamnosus GG to emu mucus). When compared to other lactic acid producing bacteria 
strains, L. rhamnosus GG was found to adhere significantly better (P < 0.05) to the 
intestinal mucus of all tested animal species (33.4% to 42.1%), with the exception of 
mucus from rainbow trout (17.6%). L. casei Shirota was found to have the poorest 
adherence of tested lactic acid producing bacteria to all animal species included in this 
study (1.1% to 1.8%). In human mucus the adhesion of L. reuteri UK1A was lowest. The 
results are expressed in Figure 2, which, for the sake of comparison, also shows a 
compilation of the results from earlier works by Tuomola et al (1999a) and 
Nikoskelainen et al (2001) . In Figure 2, the results from the work done by Tuomola and 
colleagues include adhesion studies with L. rhamnosus GG and L. casei Shirota. All the 
results from fish mucus adhesion are by Nikoskelainen and co-workers (2001) except for 
E. faecium SF68 and both L. reuteri strains. In general, no host specificity was observed 
in Study III, but there was a clear trend suggesting that the mucin adhesion of the tested 
lactic acid producing bacteria is dependent on the microorganism. (Figure 2).   
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Figure 2. Comparison of lactic acid producing bacteria adhesion percentages within 
various hosts  
Figure 2 comprises the results from Study III and studies by Tuomola et al (1999a) and 
Nikoskelainen et al (2001). 
Abbreviations: LGG: Lactobacillus rhamnosus GG; La1: Lactobacillus johnsonii La1; 
LcS: Lactobacillus casei Shirota; Lbulg: Lactobacillus bulgaricus; M74: Enterococcus 
faecium M74; SF68: Enterococcus faecium SF68; Bb12: Bifidobacterium lactis Bb12; 
UK1A: Lactobacillus reuteri UK1A; SK2A: Lactobacillus reuteri SK2A 
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8.5 IgA concentrations and their reciprocal correlations  
 
8.5.1. Serum IgA concentrations 
 
IgA concentrations in the tested sera varied from 0.7 mg ml-1 to 2.6 mg ml-1 (mean 1.8 
mg ml-1 standard deviation, SD, 0.6 mg ml-1) (Table 1, Study IV). These results are in 
line with the concentrations reported earlier (Heddle and Rowley 1975). 
 
8.5.2 Duodenal IgA concentrations 
 
In order to compensate for any disparity in duodenal sample dilutions, the IgA 
concentration of the sample was related to the concomitant concentration of total protein 
and the results are thus expressed as IgA/protein ratio. Ratios ranged from 0.009 to 0.153 
(Table 1, Study IV). A significant negative correlation (r=-0.64, p=0.0059) was found 
between duodenal IgA/protein ratios and serum IgA concentrations. Samples from 
different parts of the duodenum of the same subject had different IgA/protein ratios, 
suggesting spatial variation (Table 1, Study IV). 
 
8.5.3 Saliva IgA concentrations 
 
Also the results from the saliva samples are expressed as IgA/protein and were found to 
range from 0.009 to 1.083 (Table 1, Study IV). The correlation between duodenal and 
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salivary IgA/protein ratio was not found to be significant (p>0.05). Nor was any 
correlation observed between the salivary and duodenal IgA/protein ratios (p>0.05).  
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9. DISCUSSION 
 
9.1 Using the in vitro mucus adhesion model for adhesion studies in dogs 
 
Adhesion to the intestinal mucosa is one of the main selection criteria for potential 
probiotic microorganisms (Ouwehand et al 1999a) and was therefore the subject of the 
current study. In the study, we compared the adhesion to immobilized canine intestinal 
mucus of probiotics intended for human use (4 strains) and animal use (2 strains) and two 
L. reuteri strains isolated from dogs. The strains for human use were chosen since they 
have well documented health effects (Salminen et al 1998a) and have been shown to be 
safe (Salminen et al 1998b). 
 
The probiotics intended for human use were observed to bind to canine jejunal mucus in 
a way similar to the binding to human mucus observed earlier (Kirjavainen et al 1998, 
Tuomola et al 1999a). This suggests that the often mentioned species specificity of 
probiotics (Casas et al 1998) does not interfere with the in vitro adhesion of the tested 
strains. The probiotics intended for animal use, two E. faecium strains, exhibited a 
relatively low level of adhesion. Surprisingly, also both L. reuteri strains isolated from 
dogs showed a low level of adhesion. Based on the results obtained in this study, the 
intestinal mucus model provides a feasible method for the tentative evaluation of canine 
probiotics.  
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 9.2 Effect of the canine jejunal chyme pre-treatment on probiotic and LAB adhesion 
 
Exposure of the strains to jejunal chyme was observed to significantly reduce the 
adhesion of all tested strains, with the exception of L. johnsonii La1 and L. casei strain 
Shirota. It remains to be determined which of the components in jejunal chyme; enzymes, 
mucus, bile, etc. are responsible for the observed reduction in adhesion. However, it has 
earlier been observed that the treatment of L. rhamnosus GG with proteases reduces its 
adhesive abilities (Tuomola et al 2000), suggesting a possible role for proteolytic 
degradation in the observed effect. In addition, contact with digestive enzymes and bile 
affected the adhesion of selected probiotic LAB in vitro (Ouwehand et al 2001b). The 
observations also suggest that the adhesion observed in vitro may be quite different from 
in vivo after exposure to digestive juices. The selection criterion "adhesion” for probiotics 
should therefore perhaps be modified to "adhesion after exposure to digestive juices”. It 
also indicates that the adhesive properties of probiotics should be tested after passage 
through an intestinal model or an animal model. The jejunal chyme can in future also be 
used for simulated passage through the small intestine in order to assess, in vitro, the 
survival of potential probiotics in this part of the gastrointestinal tract. 
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9.3 In vitro competitive exclusion of pathogenic bacteria by specific probiotic and 
indigenous canine LAB 
 
The in vitro mucus adhesion of C. perfringens was significantly reduced by all tested 
LAB, which can be speculated to leading to a lower level of colonization of C. 
perfringens. the results from these studies could imply Reduced C. perfringens adhesion 
does not appear to be related to the adhesive abilities of the tested LAB. The mechanism 
for this reduction in pathogen adhesion remains therefore obscure, although it could 
imply a potential probiotic use of certain LAB strains in diminishing the number of C. 
perfringens organisms in the canine intestinal tract.    
 
The adhesion of S. Typhimurium was not significantly affected by any of the tested LAB, 
in contrast to the findings of Tuomola and colleagues (1999b). In their study, two 
strongly adhesive strains of lactobacilli significantly increased in vitro adhesion of S. 
Typhimurium to the human intestinal mucus. In study I L. Rhamnosus GG was observed 
to have a very strong adhesion also to the canine intestinal mucus. This probably 
indicates that powerful adhesion itself does not enhance the binding of S. Typhimurium 
and that increased binding to the mucus is due rather to an unelucidated mechanism, 
which could be species specific. The adhesion of S. intermedius was not altered by any of 
the LAB included in this study. 
 
Alarmingly, both Enterococcus strains were observed to significantly enhance the 
adhesion of C. jejuni. In addition to food and water borne infections, pets (particularly 
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young animals with diarrhoea) are considered to be a probable source of human C. jejuni 
infection (Ketley 1997). Campylobacter species have a typical corkscrew motility that 
enables them to penetrate through the mucus after they attach themselves to the mucosal 
surface (de Melo and Pechere 1988, Szymanski et al 1995, Sylvester et al 1996, 
Wooldridge and Ketley 1997). Adhesion to mucus receptors has been postulated to 
enhance this penetration by allowing the organism to attach on the top of the mucosal 
layer before travelling through the mucus to underlying intestinal epithelial cells 
(Sylvester et al 1996). C. jejuni lipopolysaccharide has been documented to act as an 
adhesin enabling the organism to adhere to mucin receptors, but binding to mucus varies 
among different strains (McSweegan and Walker 1986). Mucin fucose residues are 
considered chemotactic for C. jejuni (Hugdahl et al 1988). In Study II, the lack of 
adhesion enhancement with other pathogens could be the result of a different type of 
mucin adherence and could also be strain-dependent. The mechanism by which the 
enterococci enhance this first line adhesion of C. jejuni requires further investigation. 
Enhanced adhesion could be of clinical importance, as E. faecium supplementation has 
been reported to increase Campylobacter spp. counts in canine faeces (Vahjen and 
Männer 2003). 
 
Acute intestinal disorders of dogs are often treated with probiotics and many of the 
commercial products contain Enterococcus species. Study II indicates that probiotic E. 
faecium may favour the adhesion and colonization of C. jejuni in a dog’s intestine. In 
addition, also these in vitro findings have later been supported by a clinical study (Vahjen 
and Männer 2003), indicating that the in vitro adhesion model may be used as a tentative 
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method for evaluating the in vivo effects on pathogen colonization in the gut. The results 
suggest that E. faecium supplementation may make the dog a potential carrier of C. jejuni 
and a possible source for human campylobacteriosis. Enhanced colonization by this 
potential pathogen could thus be an additional risk factor for enterococci in feed or 
probiotic use. However, enterococci are widely distributed in nature and are also used in 
food technology, so not all the strains can be considered as a health risk. No probiotic 
enterococcal infections have been reported in veterinary medicine, so the risk, according 
to present knowledge, appears to be limited. However, research into probiotic therapy in 
companion animals has been scarce and it may be conceivable that possible enterococcal 
infections from probiotics have perhaps been overlooked.  Furthermore, probiotics are 
often used on debilitated animals and in conjunction with antibiotics. Thus, the potential 
risk of promoting the growth of a zoonotic pathogen should be weighed against the 
positive health effects exerted by the probiotic. The in vitro adhesion model provides a 
feasible tool for a preliminary evaluation of potential alterations in bacterial adhesion 
caused by specific probiotic strains.  
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9.4 Coaggregation 
 
Coaggregation may be one mode of communication between bacteria mediated by 
adhesins on one bacterial genus or species and equivalent receptors on another. Bacterial 
coaggregation is a well-known phenomenon in the oral cavity, where it is considered 
important for the formation of oral biofilm. This interaction can lead to rich growth, 
where the bacteria involved do not grow independently (Egland et al 2001). Some LAB 
coaggregated with Escherichia coli in the urogenital tract  (Reid et al 1988). Intestinal 
lactobacilli have also been shown to coaggregate with enteropathogens; porcine 
lactobacilli coaggregated with E. coli K88 (Spencer and Chesson 1994). Coaggregation is 
thought to be beneficial if LAB produce antimicrobials since the ability of inhibitor-
producing LAB to interact with a pathogen in close vicinity may be an important defence 
mechanism of normal flora (Reid et al 1988). In Study II, coaggregation was found to be 
an unlikely reason for enhanced binding with enterococci. However, it can be argued that 
the method used in Study II to measure coaggregation was perhaps not sensitive enough. 
The canine faecal strain L. reuteri UK1A coaggregated with S. intermedius, which is 
known to have the anal mucosa as a reservoir (Saijonmaa-Koulumies and Lloyd 1996). 
This interaction could be of ecological importance for colonization by this skin pathogen. 
Although statistically significant, the coaggregation in Study II was in general small, 
thus, its biological significance is uncertain.  
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9.5 Host specificity of in vitro Bifidobacterium and LAB adhesion to intestinal mucus 
 
The lack of host-species specificity in bifidobacteria and LAB adhesion observed in 
Study III supports the conclusions from earlier studies (Kirjavainen et al 1998, 
Nikoskelainen et al 2001). This suggests mucus adhesion of certain lactic acid producing 
bacteria to be strain dependent rather than host dependent. This concurs with earlier 
reports of LAB adhesion in different animals (Barrow et al 1980, Mäyrä-Mäkinen et al 
1983). Barrow and colleagues (1980) observed that some lactobacilli from pigs, wild boar 
and chickens adhered to pig (porcine?) squamous epithelial cells in vitro. They also noted 
that many of the LAB did not adhere to pig epithelial cells, even when the LAB were of 
porcine origin. Mäyrä-Mäkinen and colleagues (1983) found that adhesive L. fermentum 
strains isolated from calves also adhered to pig cells. It can be discussed whether the non-
adhering strains would also have been non-adhering to their original host. This was 
something the above reports did not elucidate on. Hence the adhesion divergences noted 
in these reports could actually have been due to different, species- or strain-dependent 
adhesion factors of bifidobacteria and LAB involved in the study. However, the papers 
did not systematically investigate host specificity as was done in Study III.  
 
The adhesive ability of L. rhamnosus GG was found to be superior to other bacteria 
examined in Study I. It has been reported to have excellent adhesion also to human 
mucus in vitro (Tuomola et al 1999a, Kirjavainen et al 1998) and in rainbow trout in vitro 
(Nikoskelainen et al 2001). Otherwise bifidobacteria and LAB adhesion percentages in 
rainbow trout and birds did not differ significantly from those observed in other species. 
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However, the aquatic environment of cold-water fish differs markedly from the living 
conditions of mammals and birds. Also the body temperature of birds is higher than that 
of mammals. In Study III, adhesion was examined only at 37 °C, which does not simulate 
the natural conditions of the intestines of rainbow trout or birds. The effect of incubation 
temperature on bifidobacteria or LAB adhesion in birds and fish remains to be 
determined and should be further explored. 
 
Some bacteria have well-described, clearly species-specific adhesion mechanisms, such 
as E. coli K88 fimbriae specific to pigs (Jin and Zhao 2000). On the other hand, the 
ability to bind to and colonize intestinal mucosa across species boundaries is a well-
known feature of many zoonotic pathogens: for example, the ubiquitous S. enterica 
serovars Typhimurium and Enteritis can infect a wide range of hosts (Uzzau et al 2001). 
Many animal species are also known to serve as reservoirs for C. jejuni (Nachamkin 
1997). Findings from Study III and the available literature suggest that also the adhesion 
trait of beneficial lactic acid producing bacteria may be more pronounced by the bacteria 
and intestinal microbiota rather than the host species itself. However, only in vitro 
adhesion has been evaluated in this study. In vitro adhesion cannot be considered as 
reliably predicting the in vivo colonization of intestinal microbiota because interspecies 
differences in intestinal physiology may have a marked effect on microbial colonization 
and persistence. Bacterial adhesion alone is not responsible for potential host specificity 
of intestinal microbiota. 
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Fuller (1973), Barrow and colleagues (1980) along with Mäyrä-Mäkinen and colleagues 
(1983) examined LAB adhesion to epithelial cells. Study III evaluated adhesion to 
intestinal mucus. As intestinal mucosa is the first contact surface for bacteria in the gut, 
the ability to adhere to mucus at a high level is of ecological importance to bacteria when 
colonizing the gut mucosa (Mikelsaar et al 1998). In vitro evaluation of LAB adhesion to 
intestinal mucus has been proved to be a suitable model for studying the probiotic 
adhesion (Kirjavainen et al 1998). Results from Study III imply that the attachment of the 
studied LAB and bifidobacteria to mucus is not determined by specific receptors in the 
host tissue. Although it is known, that the composition of mucus varies between animal 
species (including man), and also between different parts of the intestinal tract, human 
and canine mucus are known to share also similar characteristics (Forstner 1978, Verma 
and Davidson 1993). There may be some universal features in mucus common to 
different animal species (including man), enabling certain microbes, including LAB, to 
adhere to mucus better than others.  
 
Species specificity is considered important for the temporary colonization required to 
initiate beneficial health effects, such as immunostimulation (Salminen et al 1998). Host 
specificity was challenged earlier by Conway and co-workers (1987). They reported 
similar adhesion of lactobacilli to porcine and human epithelial cells and concluded that 
the adhesion was non-specific, suggesting the pig intestinal cells could be used in vitro to 
screen the adhesion properties of LAB intended for human consumption. Whilst the 
results obtained in Study III support the use of animal models for probiotic studies, 
further studies are needed to investigate whether determinants other than mucus adhesion 
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are required to stimulate health effects. These results may also imply that probiotic strains 
isolated from humans may be beneficial for animal use, too (Nikoskelainen et al 2001b). 
This may have important safety implications: strains shown to be safe for humans can be 
fed to livestock and pets without a potential safety concern for the consumer or owner. It 
is for additional studies to investigate whether the highly binding LAB also initiate 
similar immune effects in animals as they do in humans.  
 
In conclusion, in vitro mucus adhesion evaluation seems to be a promising model for 
tentative screening for the adhesive properties of potential canine probiotics. However, an 
in vitro model cannot truly represent the hostile conditions in the intestinal tract. To 
further validate this model for canine probiotic studies, complementary in vivo studies are 
needed.  
 
9.6 Assessing duodenal sIgA concentration in dog 
 
Results from Study IV report on a sensitive and reproducible sandwich ELISA for 
assessing duodenal and salivary sIgA and S-IgA. A significant negative correlation  
(r= -0.64, p=0.0059) was found between duodenal sIgA/protein ratios and S-IgA 
concentrations. Saliva sIgA/protein ratios did not correlate with sIgA/protein ratios of 
duodenal samples.  
 
In previous studies (Heddle and Rowley 1975, De Buysscher et al 1988), sIgA 
concentration has been determined from intestinal washes. These methods require 
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dissection of a considerable portion of intestine and are therefore not suitable for clinical 
use or serial measurements. Evaluation of intestinal sIgA production can be made by 
immunohistochemical documentation of IgA-containing cells in lamina propria. 
However, the IgA-impairment in German shepherds is believed to be due to defective 
synthesis or secretion of IgA, rather than an insufficient number of IgA-producing cells 
(Batt et al 1991). This renders the value of immunohistochemistry less applicable when 
assessing intestinal sIgA competence.  
 
In contrast, brush samples are easily obtained as part of a routine endoscopic examination 
and give more accurate information about the intestinal immunological defence capability 
than S-IgA assessment or immunohistochemical measurement of IgA-producing plasma 
cells. Brush samples provide a tool for serial measurements as well.  
A marked intra-individual variance was present in the intestinal IgA/protein ratios 
obtained in Study IV. An explanation for this may be that intestinal IgA has a patchy 
distribution instead of being an "even lining” on the gut mucosa. Also some of the IgA 
detected here could have originated from serum, and therefore not be sIgA. The lack of 
commercially available canine anti-secretory component hindered a more precise 
structural analysis of the IgA measured in Study IV. The observation of a possible 
uneven distribution of IgA on the intestinal mucosa warrants further investigation on its 
cause and biological role. 
 
Results from Study IV add more confirmation to the conception that assessment of the 
IgA competence of dogs cannot be based on serum IgA concentration. Many studies 
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associate a very low S-IgA level (less than 0.20 mg ml-1) with selective IgA deficiency 
and chronic gastrointestinal, respiratory and dermatological infections (Felsburg et al 
1985, Campbell et al 1991, Guildford 1996). This may be due to impaired IgA production 
in plasma cells, thus resulting in low IgA concentrations both in serum and on mucosal 
surfaces.  
 
Selective IgA deficiency is a common immunological disorder in dogs (Campbell et al 
1991). However, many of these individuals are asymptomatic despite a low S-IgA level 
(Felsburg et al 1985, Campbell et al 1991, Ginel et al 1993, Guildford 1996). It can be 
hypothesized that in dogs with low S-IgA, the mucosal sIgA concentration may be 
sufficient to maintain a local immune response. The S-IgA concentrations of the dogs 
involved in Study IV were within normal limits. Therefore, it remains to be examined 
whether the dogs with low S-IgA (less than 0.20 mg ml –1) concentrations do have 
compensatory high duodenal sIgA/protein levels. 
 
The role of circulating S-IgA is not fully understood. In humans, IgA can be divided into 
two subclasses, which are distributed differently between the systemic and mucosal 
immune systems (Heremans 1974). It is not known whether such classification applies to 
canine IgA, too. If similar subclasses are present also in dogs, it can be hypothesized that 
sIgA is focused mainly on antimicrobial defense on the mucosal surface and that S-IgA 
acts primarily as a regulator of immunity. Although both canine sIgA and S-IgA originate 
mostly from gut-associated lymphoid tissue (Heremans 1974), they may be regulated 
independently and therefore there is no correlation between sIgA and S-IgA 
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concentrations. Mestecky and colleagues (1999) suggested that circulating S-IgA has an 
important role in preventing an immune response-inflammation cycle, which can result in 
tissue damage and chronic inflammatory disease.  
 
Based on the significant negative correlation between sIgA and S-IgA found in Study IV, 
it can be postulated that S-IgA is needed to eliminate hostile invaders from the circulatory 
system and body tissues if sIgA fails and intruding antigens are able to penetrate the 
epithelium. In this case, S-IgA is preferred to IgG and IgM because of its milder 
response, which is less likely to cause damage to the host’s tissue (Willard 1992, 
Mestecky et al 1999). 
 
Study IV found no correlation between duodenal and saliva sIgA levels, rendering saliva 
sIgA assays dubious for assessing mucosal sIgA concentration in the gut. Certain animal 
models have shown that mucosal immunization leads also to serum IgA response and 
may induce mucosal IgA responses in distant mucosal surfaces, too (Bergmeier et al 
1995, Wu and Russel 1998, Jakobsen et al 2002). However, there has been divergence in 
the results: the responses are not always comparable between different mucosal surfaces 
and serum (Currie et al 2001, Heddle and Rowley 1975).  
 
It has been suggested that the majority of sIgA found on mucosal surfaces emerges from 
local synthesis rather than from the transport of S-IgA from the blood, stressing the 
importance of local sIgA production (Mestecky 1993). This could explain the lack of 
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correlation between duodenal and saliva sIgA concentrations observed in Study IV and 
further supports the need for an easy method for assessing intestinal sIgA production. 
 
Large day-to-day and diurnal variations in saliva IgA have been reported (Ginel et al 
1993). Whether this fluctuation also applies to the intestinal tract needs to be determined 
as it may influence the interpretation of study results in the future. The method described 
in Study IV to sample the intestinal mucosa is gentle and allows for the examination of 
temporal variation.  
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10. CONCLUSIONS 
 
I    Studies on the adhesive properties of probiotic and indigenous canine LAB in 
intestinal mucus model in vitro led to following conclusions: 
 
1.   Intestinal mucus model utilized in human probiotic studies is applicable also 
when examining the adhesive properties of potential probiotic LAB intended for 
canine use. This in vitro adhesion assay may provide a basis for studying the 
efficacy of these probiotics in dogs. Canine jejunal chyme is a convenient source 
of intestinal mucus. Some probiotics intended for human use were found to 
interact well with immobilized canine intestinal mucus.    
 
2. Exposure of the strains to jejunal chyme was observed to significantly reduce the 
adhesion of all tested strains, with the exception of L. johnsonii La1 and L. casei 
strain Shirota. Therefore, adhesion observed in vitro may be quite different from 
that in in vivo after exposure to digestive juices. It remains to be determined 
which of the components in jejunal chyme; enzymes, mucus, bile, etc. are 
responsible for the observed reduction in adhesion. Canine jejunal chyme is a 
convenient source of intestinal mucus and can be used to assess the effects of 
digestion on probiotics in vitro.  
 
3. The canine mucus adhesion model provides a tool for the preliminary evaluation 
of competitive exclusion of canine intestinal pathogens in vitro. The LAB tested 
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may be beneficial in reducing the number of C. perfringens organisms in the 
canine intestine. These LAB should be evaluated further for the treatment and/or 
prevention of disease in vivo. The observed increase in in vitro mucus adhesion of 
C. jejuni caused by the tested enterococci may be a cause for concern. Enhanced 
C. jejuni adhesion is a new potential risk factor of E. faecium and requires further 
investigation. This finding emphasizes the importance of establishing safety 
guidelines for probiotics intended for both animal and human use. The in vitro 
mucus adhesion model provides a feasible method for the tentative evaluation of 
potential canine probiotics. 
 
4. Mucus adhesion properties are more dependent on the LAB strain than on the host 
animal, thus suggesting that mucus adhesion mechanisms may share some 
universal features common to mammals, birds and fish. This may suggest that the 
animal models in probiotic adhesion assays may be more reliable than previously 
thought. The documented positive health effects facilitated by adherent probiotics 
in humans may also denote the possibility of similar outcomes in other species 
and vice versa. 
 
II   The study to develop a method for intestinal sIgA assay yielded a novel method for 
repeated sampling of the duodenal mucosa to directly determine the intestinal immune 
response. This method may be utilized in further studies when examining the IgA-
modulating properties of well-adhering, potential probiotics aimed for canine use. A 
marked variance in sIgA concentrations was measured from different sites of duodenal 
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mucosa. In addition, it can be concluded, that neither S-IgA nor salivary sIgA are suitable 
parameters for assessing duodenal sIgA competence in the dog.  
 
Based on the findings of the study, it is clear that further studies are needed to evaluate 
the potential beneficial health effects of lactic acid producing bacteria intended for dogs. 
Certain probiotics may be useful in competitive exclusion of pathogenic C. perfringens. 
In vivo studies would benefit in validating the in vitro methods.  
 
The immunomodulatory effects documented in humans are certainly of special interest 
also in veterinary science. This may be the most important field of probiotic science in 
future studies on dogs. 
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